These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556 [TBL] [Abstract][Full Text] [Related]
23. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD). Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346 [TBL] [Abstract][Full Text] [Related]
24. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones. Luo H; Cao L; Liang X; Du A; Peng T; Li H Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620 [TBL] [Abstract][Full Text] [Related]
25. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease. Zuleta A; Vidal RL; Armentano D; Parsons G; Hetz C Biochem Biophys Res Commun; 2012 Apr; 420(3):558-63. PubMed ID: 22445760 [TBL] [Abstract][Full Text] [Related]
26. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice. Pitzer M; Lueras J; Warden A; Weber S; McBride J Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261 [TBL] [Abstract][Full Text] [Related]
27. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230 [TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway. Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468 [TBL] [Abstract][Full Text] [Related]
29. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease. Dufour BD; McBride JL Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559 [TBL] [Abstract][Full Text] [Related]
30. Targeting the proteostasis network in Huntington's disease. Soares TR; Reis SD; Pinho BR; Duchen MR; Oliveira JMA Ageing Res Rev; 2019 Jan; 49():92-103. PubMed ID: 30502498 [TBL] [Abstract][Full Text] [Related]
31. Copper enhances aggregational toxicity of mutant huntingtin in a Drosophila model of Huntington's Disease. Lobato AG; Ortiz-Vega N; Zhu Y; Neupane D; Meier KK; Zhai RG Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166928. PubMed ID: 38660915 [TBL] [Abstract][Full Text] [Related]
33. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease. Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248 [TBL] [Abstract][Full Text] [Related]
34. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023 [TBL] [Abstract][Full Text] [Related]
35. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease. Ban JJ; Chung JY; Lee M; Im W; Kim M Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533 [TBL] [Abstract][Full Text] [Related]
36. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Keller CG; Shin Y; Monteys AM; Renaud N; Beibel M; Teider N; Peters T; Faller T; St-Cyr S; Knehr J; Roma G; Reyes A; Hild M; Lukashev D; Theil D; Dales N; Cha JH; Borowsky B; Dolmetsch R; Davidson BL; Sivasankaran R Nat Commun; 2022 Mar; 13(1):1150. PubMed ID: 35241644 [TBL] [Abstract][Full Text] [Related]
37. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin. Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943 [TBL] [Abstract][Full Text] [Related]
39. Autophagy Activation by Transcription Factor EB (TFEB) in Striatum of HDQ175/Q7 Mice. Vodicka P; Chase K; Iuliano M; Tousley A; Valentine DT; Sapp E; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M J Huntingtons Dis; 2016 Oct; 5(3):249-260. PubMed ID: 27689619 [TBL] [Abstract][Full Text] [Related]
40. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis. Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J Elife; 2021 Apr; 10():. PubMed ID: 33871358 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]